IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 1196 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Article in PDF (218 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   Abstract
   Introduction
   Methods
   Results
   Discussion
   References
   Article Tables

 Article Access Statistics
    Viewed4424    
    Printed86    
    Emailed1    
    PDF Downloaded225    
    Comments [Add]    
    Cited by others 2    

Recommend this journal

 


 
ORIGINAL ARTICLE
Year : 2009  |  Volume : 75  |  Issue : 4  |  Page : 363-367

Comparison of seropositivity of human T lymphotropic virus type 1 in mycosis fungoides patients and normal volunteers: A case-control study and review of literature


1 Razi Skin Hospital, Department of Dermatology, Medical Sciences/University of Tehran, Tehran, Iran
2 Center for Research & Training in Skin Diseases & Leprosy, Medical Sciences/University of Tehran, Tehran, Iran
3 Razi Skin Hospital, Department of Dermatology and Center for Research & Training in Skin Diseases & Leprosy, Medical Sciences/University of Tehran, Tehran, Iran

Date of Web Publication3-Jul-2009

Correspondence Address:
Farzam Gorouhi
Unit 10, #19, Boostan Building, Sharifimanesh Ave., Elahieh St., Tehran
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.53131

Rights and Permissions

  Abstract 

Background: There have been controversial reports about the possible association between mycosis fungoides (MF), its leukemic variant Sιzary syndrome (SS) and human T lymphotropic virus type 1 (HTLV-1) in different geographical regions. Aims: The purpose of this study was to explore any association between MF and presence of HTLV-1 infection in Iran. Methods: In a case-control setting, 150 clinically and histopathologically proven MF patients had been admitted to the tertiary referral skin center during a 10-year period and another 150 normal volunteers had been compared with each other for the presence of HTLV-1 infection. Enzyme-linked immunosorbent assay (ELISA) was used to detect antibodies against HTLV-1, and positive results were confirmed with western blotting. Results: Only three MF patients had HTLV-1 infection, whereas two cases of normal subjects had the infection ( P > 0.05). The only three seropositive MF patients were male and from North-Eastern Iran . Conclusion: This study showed that MF does not correlate with HTLV-1 infection in Iran.


Keywords: Mycosis fungoides, Enzyme-linked immunosorbent assay, Human T-cell lymphotropic virus type 1, Western blot


How to cite this article:
Seirafi H, Farnaghi F, Firooz A, Mostafa S, Talaei-Khoei M, Davari P, Gorouhi F. Comparison of seropositivity of human T lymphotropic virus type 1 in mycosis fungoides patients and normal volunteers: A case-control study and review of literature. Indian J Dermatol Venereol Leprol 2009;75:363-7

How to cite this URL:
Seirafi H, Farnaghi F, Firooz A, Mostafa S, Talaei-Khoei M, Davari P, Gorouhi F. Comparison of seropositivity of human T lymphotropic virus type 1 in mycosis fungoides patients and normal volunteers: A case-control study and review of literature. Indian J Dermatol Venereol Leprol [serial online] 2009 [cited 2019 Jun 25];75:363-7. Available from: http://www.ijdvl.com/text.asp?2009/75/4/363/53131



  Introduction Top


Mycosis fungoides (MF) is an infrequent, T-cell lymphoma first reported by Alibert [1] in the early 1800s. Primarily, this disease is manifested with plaques, being the typical feature, in skin. Then, it might advance after a variable period of time to cutaneous tumors and invade to visceral sites and lymph nodes [2] Sιzary syndrome (SS) is an erythrodermic, leukemic variant of MF accompanied with presence of circulating tumor cells in blood. [3]

The incidence of MF is increasing. In the United States, it has been about 0.4 cases per 100 000 populations, [4] and there has been about 1000 new cases diagnosed every year. [3] Mostly MF/SS is a disorder of middle-aged adults[5] and male to female ratio is 2.2 : 1. [4]

The certain etiology of MF is unknown and has remained controversial. A range of theories point the finger at infectious agents, oncogenes, cytokines or occupational or environmental exposures. [1] Several viruses have been implicated in the pathogenesis of MF/SS. There is probable convincing evidence that human T-cell lymphotrophic virus-1 (HTLV-1) is associated with MF; [6] however, these observations are still a matter of debate. One of the prominent supporting evidence of association between MF and HTLV-1 has shown HTLV-1 DNA sequences in peripheral blood mononuclear cells and skin lesions of some patients with MF. [7],[8] On the other hand, some studies have claimed no role for HTLV-1 in pathogenesis of MF. [9]

HTLV-1 was first isolated and typified in 1980. This retrovirus provokes the proliferation of CD4+ T-cells and transforms them into tumor cells, mainly resulting in adult T-cell leukemia. HTLV-1 is spread globally with some high endemic foci in southern Japan, intertropical Africa, the Caribbean, certain areas of southern America, Melanesia and Middle East. [10] Mashhad, a city in North-eastern Iran, is suspected for being the 'epicenter' of HTLV-1 in Middle East and probably in Asia. It was found that the HTLV-1 infection in Israel is limited to Jews originating from Iran, mostly from Mashhad. [11] Therefore, controversy of association of MF and HTLV-1 from one side and endemic status of MF in Iran from another side, persuaded us to retrospectively investigate on the rate of HTLV-1 infection in Iranian MF patients and compare it with its normal rate in Iranian population in a case-control study.


  Methods Top


Patients

One hundred and fifty clinically and histopathologically proven MF patients who were admitted to the tertiary referral skin center (Razi hospital) in Tehran, Iran during a 10-year period (between November 1994 and October 2004) were reviewed. A control group of 150 healthy first time blood donors were selected. These controls were matched with MF group according to their sex and age. None of the controls had a history of any skin or serious general disease at the time of blood sampling. All the control samples were retrospectively obtained from different branches of national blood transfusion center, nationwide. Consent of the patients and ethical committee clearance was obtained.

The country was divided into five geographical areas: North-eastern, South-eastern, North-western, South-western and central parts. Any occupation in the 10-year period prior to the first clinical evidence of MF was recorded. Personal and family history of malignancies was also investigated.

Diagnosis and staging of MF

The diagnosis of MF would have been established in a patient if any of these histological features were seen: a) Presence of atypical lymphoid cells that are slightly larger than normal lymphocytes and possess hyperchromatic, irregularly contoured (convoluted) nuclei; b) Presence of individual haloed atypical lymphocytes within the epidermis; c) Presence of single lymphoid cells linearly arranged along the basal layer of the epidermis with pagetoid spread; d) Presence of an increased or skewed number of lymphocytes (not necessarily atypical) relative to typical dermatitis, distributed singly or in small collections in an epidermis devoid of spongiotic microvesiculation; e) Presence of papillary dermal fibrosis.

World Health Organization (WHO) classification [12] and International Society for Cutaneous Lymphomas (ISCL) [13] tumor node metastasis (TNM) staging were used for this study.

Diagnostic laboratory methods for HTLV-1

The sera of both groups were tested for antibodies to HTLV-1 structural proteins (p19) by Enzyme-linked Immunosorbent Assay (ELISA, MP Biomedicals, OH, USA) and each ELISA positive result was confirmed by western blotting method (Gene Lab Diagnostic Pvt Ltd., Singapore). The HTLV-1 seropositivity criteria were reactive to a GAG protein (P19) and an envelope protein (rgp46-I).

Statistical analysis of data

The obtained and recorded data were entered in SPSS 11.0 for Windows software (SPSS Inc, Chicago, IL, USA). Data have been reported as mean standard deviation (SD), wherever necessary. According to normal distribution of patient's age, which was tested by one-sample Kolmogorov-Smirnov test, it was compared in both groups by independent sample t test. Patients' gender was compared between two groups using Chi-square test. Fisher's exact test was performed to compare the geographical distribution of residence and rate of HTLV-1 infection. Confidence intervals were measured for some proportions. Only two-sided probability values less than 0.05 were considered as significant.


  Results Top


Mean ages of MF and healthy groups were 44.7 16.2 and 42.3 17.1, respectively ( P > 0.05) Male-female ratios of MF and healthy groups were 1.20 and 1.15, respectively ( P > 0.05). Male subjects had a peak at sixth decade of age and females at fourth decade in both groups. Thirty five (41.6%) male MF patients were farmer and 63 (95.5%) female MF patients were housekeeper. Five (3.3%) MF patients had a history of malignancy: Two with Kaposi's sarcoma and one for Hodgkin's lymphoma, non-Hodgkins lymphoma and leukemia each. Healthy controls did not have a history of malignancy at all except one with small cell carcinoma.

The majority of patients with MF (113 [75.3%]) were in the initial stages (IA, IB, IIA); however, the three seropositive patients were in advanced age and stage of the disease. Two patients were in stage IIB (tumor stage) and one in stage III (erythroderma).

Antibodies to HTLV-1 were found in the sera of only 3 (2.0%) patients with MF by ELISA, which confirmed by blotting and only 2 (1.3%) control volunteers had these antibodies [[Table 1], P > 0.05].


  Discussion Top


Mycosis fungoides is considered to be a sporadic disease. Persistent antigenic stimulation has been proposed as an initial event in MF, but the nature of the involved antigen(s) is unknown. [14] A pathogenic role for a variant or defective retrovirus has been suggested but remains unclear. The etiological role of HTLV-1 in adult T-cell leukemia lymphoma has been firmly established. Poeiz et al . were the first to isolate HTLV-1 from a patient thought to have MF but later diagnosed as having adult T-cell lymphoma leukemia. [15] Later, Pancake and Zucker-Franklin [16] demonstrated HTLVI-1 tax sequences in cell lysates from peripheral blood mononuclear cells of 10 patients with MF. In another study, they showed both Pol and Tax sequences in 46 of 50 MF patients. [17] A study conducted in Germany suggested that HTLV-1 plays a cofactor role in some MF or SS patients. [18]

Zucker-Franklin et al . suggested that the prevalence of infection with HTLV-1, particularly when efforts are made to detect Tax sequences may be considerably higher than is currently believed. Although most patients with the cutaneous T-cell lymphoma, MF, are seronegative for HTLV-1, when tested by assays that measure only antibodies to the viral structural proteins, the majority of such patients harbor HTLV-l-related Pol and Tax proviral sequences that encode proteins not included in routinely used serologic tests. Tax mRNA has also been detected in their peripheral blood mononuclear cells. [19] In contrast to these supportive studies, some investigations showed no role for HTLV-1 in MF pathogenesis. [20] Fuhihara et al. proposed that MF and SS were not associated with any of the known prototypic human retroviruses. [21]

A study in Pakistan concluded that the prevalence of MF in Pakistan population is comparable to the Western data, and that Epstein-Barr virus (EBV) and not HTLV-1 association to MF cases was higher than in Western studies. [22] A large study conducted by Bzarachi et al. on 127 patients (85 MF, 28 SS, 5 Sιzary cell leukemia, 4 lymphomatoid papulosis and 5 unspecified cutaneous T-cell lymphomas) originating from Europe (France, Spain, UK, Portugal) or from USA (California) for the presence of HTLV-1 infection markers obviously point toward that MF and SS were not associated with HTLV-1 infection. [9] In lymphoproliferative disorders, except adult T-cell leukemia (ATL), [23] the seronegativity for HTLV-1 is common. However, more sensitive methods such as ELISA have recently enabled to show seropositivity for HTLV-1 up to 30% in various leukemia/lymphoma patients including MF. [6],[24] In a study from Japan, 128 DNA specimens of fresh skin lesion have been examined. They showed that none had serum HTLV-1 antibodies to clarify the relationship between HTLV-1 and cutaneous T-cell lymphoma (CTCL) in Japan. [25] To this end, peripheral blood mononuclear cells from HTLV-1 seronegative Tax-only-positive MF patients or from healthy Tax-only-positive blood donors were injected into adult rabbits, an established animal model for HTLV-1 infection. The peripheral blood mononuclear cells of all injected rabbits became Tax sequence positive. These observations proposed that HTLV-1 Tax can be transmitted by Tax-only-positive mononuclear cells. [26]

There are several possible explanations for these contradictory results: (i) Technical problems such as contamination of PCR reactions can easily occur especially in PCR studies; (ii) Many positive bands can be detected if the stringency of PCR is low, [25] unless the complete sequencings for the PCR products are done; [27] (iii) Differences in the selections of patients; (iv) The involvement of the retrovirus related to but different from HTLV-1, deleted forms of HTLV-1genome might exist in the genomic DNA of CTCL patients. [28] Lastly, in the positive studies most of the HTLV-1 DNAs were proved not in the fresh specimen but in the cultured cells including non T-cell lines. [28] During the cultivating procedure, not only colony expansions but also modifications of the culturing cells can occur. Thus the DNA derived from these cell lines does not exactly reflect conditions in the original CTCL. Furthermore, HTLV-1 sequences have been detected even in the squamous cell carcinomas of the skin [29] proposing that an opportunistic or a coincidental infection of HTLV-1 should be considered.

In the present study, after conducting an antibody ELISA test of the 150 MF patients, only 3 (2%) positive responses have been reported and 2 (1.3%) individuals in the control group had antibodies to HTLV-1. Analysis confirmed the lack of any statistically significant association between MF and HTLV-1, and in conclusion evidence for a primary etiologic role of this virus in MF is lacking.

A wide range of geographical distribution have been reported by both patients and control subjects, two seropositive patients with MF were from east-northern Iran: One from Mashhad and the other from QaemShahr. No obvious or significant differences were seen with regard to endemic area Mashhad for HTLV-1. In contrast, a study had described a high overall risk of HTLV-1 infections in Israelis originating from the city of Mashhad. [30]

The prevalence of HTLV-1 infection in Mashhad is estimated to be 2-3% in the whole population and 0.7% in blood donors. [31],[32] It has been shown that some HLA alleles, which are more common in Mashhad residents, can increase the risk of occurrence and severity of HTLV-1. [33]

A more recent study from Germany in over 82 patients with primary cutaneous lymphoma, has observed an elevated risk for the development of a secondary lymphoproliferative disorder even without previous chemotherapy. [34]

In studies of this type, it is always important to guard against selection bias (epidemiological trends) in the population studied. The major limitation of this study has been its case-control design. It is hardly concluded a definite fact out of a case-control study design. Taken together, our study shows that there is no significant clustering of other malignancy in patients affected with MF.

 
  References Top

1.Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood 1996;88:2385-409.  Back to cited text no. 1    
2.Edelson RL. Cutaneous T cell lymphoma: Mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol 1980;2:89-106.  Back to cited text no. 2    
3.Kim YH, Hoppe RT. Mycosis fungoides and the Sezary syndrome. Semin Oncol 1999;26:276-89.  Back to cited text no. 3    
4.Weinstock MA, Horm JW. Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA 1988;260:42-6.  Back to cited text no. 4    
5.Epstein EH Jr, Levin DL, Croft JD Jr. Lutzner MA. Mycosis fungoides. Survival, prognostic features, response to therapy, and autopsy findings. Medicine (Baltimore) 1972;51:61-72.  Back to cited text no. 5    
6.Wantzin GL, Thomsen K, Nissen NI, Saxinger C, Gallo RC. Occurrence of human T cell lymphotropic virus (type I) antibodies in cutaneous T cell lymphoma. J Am Acad Dermatol 1986;15:598-602.  Back to cited text no. 6    
7.Ranki A, Niemi KM, Nieminen P, Krohn K. Antibodies against retroviral core proteins in relation to disease outcome in patients with mycosis fungoides. Arch Dermatol Res 1990;282:532-8.  Back to cited text no. 7    
8.Manca N, Piacentini E, Gelmi M, Calzavara P, Manganoni MA, Glukhov A, et al . Persistence of human T cell lymphotropic virus type 1 (HTLV-1) sequences in peripheral blood mononuclear cells from patients with mycosis fungoides. J Exp Med 1994;180:1973-8.  Back to cited text no. 8    
9.Bazarbachi A, Soriano V, Pawson R, Vallejo A, Moudgil T, Matutes E, et al . Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: An international study. Br J Haematol 1997;98:927-33.  Back to cited text no. 9    
10.Taylor GP. The epidemiology and clinical Impact of HTLV infections in Europe. AIDS Rev 1999;1:195-204.  Back to cited text no. 10    
11.Voevodin A, Gessain A. Common origin of human T-lymphotropic virus type-I from Iran, Kuwait, Israel, and La Reunion Island. J Med Virol 1997;52:77-82.  Back to cited text no. 11    
12.Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al . WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-85.  Back to cited text no. 12    
13.Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al . Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713-22.  Back to cited text no. 13    
14.Tan RS, Butterworth CM, McLaughlin H, Malka S, Samman PD. Mycosis fungoides--a disease of antigen persistence. Br J Dermatol 1974;91:607-16.  Back to cited text no. 14    
15.Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980;77:7415-9.  Back to cited text no. 15    
16.Pancake BA, Zucker-Franklin D. The difficulty of detecting HTLV-1 proviral sequences in patients with mycosis fungoides. J Acquir Immune Defic SynDr. Hum Retrovirol 1996;13:314-9.  Back to cited text no. 16    
17.Pancake BA, Zucker-Franklin D, Coutavas EE. The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients. J Clin Invest 1995;95:547-54.  Back to cited text no. 17    
18.Shohat M, Hodak E, Hannig H, Bodemer W, David M, Shohat B. Evidence for the cofactor role of human T-cell lymphotropic virus type 1 in mycosis fungoides and Sezary syndrome. Br J Dermatol 1999;141:44-9.  Back to cited text no. 18    
19.Pancake BA, Wassef EH, Zucker-Franklin D. Demonstration of antibodies to human T-cell lymphotropic virus-I tax in patients with the cutaneous T-cell lymphoma, mycosis fungoides, who are seronegative for antibodies to the structural proteins of the virus. Blood 1996;88:3004-9.  Back to cited text no. 19    
20.Pawlaczyk M, Filas V, Sobieska M, Gozdzicka-Jozefiak A, Wiktorowicz K, Breborowicz J. No evidence of HTLV-I infection in patients with mycosis fungoides and Sezary syndrome. Neoplasma 2005;52:52-5.  Back to cited text no. 20    
21.Fujihara K, Goldman B, Oseroff AR, Glenister N, Jaffe ES, Bisaccia E, et al . HTLV-associated diseases: Human retroviral infection and cutaneous T-cell lymphomas. Immunol Invest 1997;26:231-42.  Back to cited text no. 21    
22.Noorali S, Yaqoob N, Nasir MI, Moatter T, Pervez S. Prevalence of mycosis fungoides and its association with EBV and HTLV-1 in Pakistanian patients. Pathol Oncol Res 2002;8:194-9.  Back to cited text no. 22    
23.Yamaguchi K. Human T-lymphotropic virus type I in Japan. Lancet 1994;343:213-6.  Back to cited text no. 23    
24.Srivastava BI, Gonzales C, Loftus R, Fitzpatrick JE, Saxinger CW. Examination of HTLV-1 ELISA-positive leukemia/ lymphoma patients by western blotting gave mostly negative or intermediate reaction. AIDS Res Hum Retroviruses 1990;6:617- 27.  Back to cited text no. 24    
25.Kikuchi A, Nishikawa T, Ikeda Y, Yamaguchi K. Absence of human T-lymphotropic virus type I in Japanese patients with cutaneous T-cell lymphoma. Blood 1997;89:1529-32.  Back to cited text no. 25    
26.Zucker-Franklin D, Pancake BA, Lalezari P, Khorshidi M. Transmission of human T-cell lymphotropic virus type 1 tax to rabbits by tax-only-positive human cells. Clin Diagn Lab Immunol 2000;7:274-8.  Back to cited text no. 26    
27.Whittaker SJ, Luzzatto L. HTLV-1 provirus and mycosis fungoides. Science 1993;259:1470  Back to cited text no. 27    
28.Hall WW, Liu CR, Schneewind O, Takahashi H, Kaplan MH, Roupe G, et al . Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science 1991;253:317-20.  Back to cited text no. 28    
29.Chan WC, Hooper C, Wickert R, Benson JM, Vardiman J, Hinrichs S, et al . HTLV-I sequence in lymphoproliferative disorders. Diagn Mol Pathol 1993;2:192-9.  Back to cited text no. 29    
30.Miller M, Achiron A, Shaklai M, Stark P, Maayan S, Hannig H, et al . Ethnic cluster of HTLV-I infection in Israel among the Mashhadi Jewish population. J Med Virol 1998;56:269-74.  Back to cited text no. 30    
31.Safai B, Huang JL, Boeri E, Farid R, Raafat J, Schutzer P, et al . Prevalence of HTLV type I infection in Iran: A serological and genetic study. AIDS Res Hum Retroviruses 1996;12:1185-90.  Back to cited text no. 31    
32.Abbaszadegan MR, Gholamin M, Tabatabaee A, Farid R, Houshmand M, Abbaszadegan M. Prevalence of human T-lymphotropic virus type 1 among blood donors from Mashhad, Iran. J Clin Microbiol 2003;41:2593-5.  Back to cited text no. 32    
33.Hosseini-Farahabadi S, Tavakkol-Afshari J, Rafatpanah H, Farid Hosseini R, Khaje Daluei M. Association between the polymorphisms of IL-4 gene promoter (-590C>T), IL-13 coding region (R130Q) and IL-16 gene promoter (-295T>C) and allergic asthma. Iran J Allergy Asthma Immunol 2007;6:9-14.  Back to cited text no. 33    
34.Hallermann C, Kaune KM, Tiemann M, Kunze E, Griesinger F, Mitteldorf C, et al . High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Ann Hematol 2007;86:509-15.  Back to cited text no. 34    



 
 
    Tables

  [Table 1]

This article has been cited by
1 Malignant diseases and mortality in blood donors infected with human T-lymphotropic virus type 1 in Israel
Shmuel Stienlauf,Vered Yahalom,Eilat Shinar,Yechezkel Sidi,Gad Segal,Eli Schwartz
International Journal of Infectious Diseases. 2013; 17(11): e1022
[Pubmed] | [DOI]
2 Frequency of human T-Cell lymphotropic virus (HTLV) type 1 and 2 infection in HIV infected patients
Ramezani, A., Aghakhani, A., Banifazl, M., Boland-Ghamat, Z., Foroughi, M., Gachkar, L., Khadem-Sadegh, A., Mohraz, M.
Iranian Journal of Pathology. 2012; 7(1): 9-13
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow